Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
22/08/2024 13:05
Aug 22 (Reuters) - Palatin Technologies Inc PTN.A :
* FIRST PATIENT DOSED IN PHASE 2 CLINICAL STUDY OF PALATIN'S
BREMELANOTIDE CO-ADMINISTERED WITH TIRZEPATIDE (GLP-1) FOR THE
TREATMENT OF OBESITY
* PALATIN TECHNOLOGIES INC - TOPLINE RESULTS EXPECTED IN 1Q
CALENDAR YEAR 2025
* PALATIN TECHNOLOGIES INC: COMPLETE ENROLLMENT CURRENTLY
EXPECTED
IN 3Q 2024
Source text for Eikon: ID:nPnz58J3a
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity